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INTRODUCTION
The World Health Organization (WHO) was informed
by the Chinese Ministry of Health on 11 February 2003
that there were 305 cases of an acute respiratory
syndrome of unknown etiology (WHO 2003a). These
cases occurred in six municipalities in Guangdong
Province of southern China during 16 November 2002 -
9 February 2003 (WHO 2003a).
As determined by a consensus of worldwide public
health officials in March 2003, surveillance case defi-
nitions for Severe Acute Respiratory Syndrome (SARS)
includes both "suspect" and "probable" cases (MMWR
2003a; CDC 2003a) (See below).
As of late February 2003, the Centers for Disease
Control and Prevention (CDC) and WHO referred to the
new outbreak as Severe Acute Respiratory Syndrome
(SARS) (MMWR 2003a). By 17 April 2003, there were
3,389 suspected/probable cases of SARS in 25 countries
with 165 deaths or a case-fatality proportion of 5%
(WHO 2003b). By 1 May 2003, at least 5,865 suspected/
probable cases of this disease had been reported to
WHO from 27 different countries. At that time there
were 391 deaths (case-fatality proportion of 6.7%)
(WHO 2003c). As of 30 April 2003, there had been 289
cases of suspect or probable (only 56 were probable)
SARS reported in the US with no known deaths (MMWR
20030. On 8 May 2003, WHO assigned a case-fatality
rate of 15% (Foxnews 2003), greater than the 3% ini-
tially assigned by WHO (MMWR 2003b), and far greater
than the 2.8% fatality rate of the 1918 Influenza pan-
demic. This appears rather surprising considering that
the latest WHO data (7 May 2003) indicates 495 deaths
world-wide with 6,903 suspect/probable cases resulting
in a 7% case-fatality rate (WHO 2003d).
CASE DEFINITIONS
A "suspect" case of SARS is defined as a respiratory
illness of unknown etiology with onset since 1 February
2003, and with the following criteria (MMWR 2003a):
1) measured temperature >100.4°F (>38°C); 2) one or
more clinical findings of respiratory illness (for example,
cough, shortness of breath, difficulty breathing, hypoxic,
or radiographic findings of either pneumonia or acute
respiratory distress syndrome); and 3) travel within ten
days of onset of symptoms to an area with suspected
or documented community transmission of SARS. This
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would exclude areas with secondary cases limited to
health care workers, direct household contacts, or close
contact within ten days of onset of symptoms with
either a person with a respiratory illness and travel to a
SARS area, or a person under investigation or suspected
of having SARS.
A "probable" case is defined as a suspect case with
either radiographic evidence of pneumonia or respiratory
distress syndrome or autopsy findings consistent with
respiratory distress syndrome without an identifiable
cause (CDC 2003a). On 29 April 2003, CDC's interim
surveillance case definition for SARS had been updated
to include laboratory criteria for evidence of infection
with the SARS-associated coronavirus (MMWR 20030.
The basis of the revised definition is that the virus can
now be detected by polymerase chain reaction (PCR),
serological methods, or viral isolation methods. Al-
though, at this time, no instances of SARS-associated
coronavirus had been detected in persons who were
asymptomatic, there remains the possibility of "sub-
clinical" infection. In such cases laboratory detection
may be able to identify patients with mild respiratory
illness or those who are asymptomatic.
CLINICAL DESCRIPTION
What is the clinical description of SARS? Most patients
with SARS have traveled to Mainland China, Hong Kong,
Singapore, or Hanoi. More recently there has been an
alarming increase in SARS cases in and around Toronto,
Ontario (MMWR 2003e). Close contact with a SARS
patient can also be a risk factor. SARS generally begins
with a fever above 100.4° F and may include headache,
malaise, and myalgia. The fever may be accompanied
with chills and rigors. Rash, neurologic, and gastro-
intestinal findings are usually absent but several patients
have had diarrhea. The incubation period appears to be
2-7 days although several cases may have had a 10-day
incubation period. Three to seven days after initial symp-
toms appear, a lower respiratory phase begins with
onset of dry, nonproductive cough and dyspnea pos-
sibly progressing to hypoxemia (CDC 2003b and MMWR
2003c)). As many as 20% of such patients will require in-
tubation and placement on a ventilator (MMWR 2003c).
Laboratory results early in the course of SARS usually
show a decrease in lymphocytes with total white blood
cell counts either normal or decreased. Later, during the
respiratory phase of disease, about half of the patients
show leukopenia and thrombocytopenia (MMWR
2003a). Creatine phosphokinase and hepatic trans-
aminase are elevated. Chest x-rays may be normal
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throughout the illness (MMWR 2003d). Many patients,
however, will present with patchy interstitial infiltrates
during the lower respiratory phase of disease when
viewed in lung radiograms. Severity of the illness is highly
variable, ranging from mild illness to death.
CAUSE OF DISEASE
What is the cause of the infection? On 24 March 2003,
CDC announced that the causative agent of SARS was
identified as a previously unrecognized coronavirus
(MMWR 2003b). Initial identification was made by elec-
tron microscopy and confirmed by direct immuno-
staining, indirect immunofluorescent antibody assay, and
reverse transcriptase-polymerase chain reaction with
sequencing of a portion of the polymerase gene (MMWR
20030- The family of Coronaviruses has been poorly
studied because they are difficult to culture. Until now,
coronaviruses have been associated with the "common
cold" (Wilson and others 2001) and diarrhea (Brooks and
others 2001) in humans and infections in animals,
worldwide. The case for coronaviruses causing more
severe disease in humans, such as bronchitis, was very
tenuous (Tan 2002).
The Coronaviruses (Brooks and others 2001; Murry
and others 1998) have a lipoprotein envelope and are
shaped as long helical structures that measure 80 to 220
nm. These viruses get their name from the solar corona-
like appearance surrounding the virion that is produced
by the 20 nm long glycoprotein, petal-shaped projections
that appear on the surface of the envelope. The virus
contains a single-stranded positive sense RNA (like
messenger RNA) that is the longest genome known
among RNA viruses (approximately 30,000 bases). If the
agent of SARS replicates like other human corona-
viruses, it will do so in the cytoplasm of the infected
cell. The virus would attach itself to cell receptors by
means of the glycoprotein spikes on the viral envelope.
The virus is then internalized by endocytosis. After
uncoating, the viral genomic RNA is translated to produce
an RNA dependent RNA polymerase in the cytoplasm.
The new viral polymerase transcribes about seven
messenger RNAs, specific for viral proteins. The newly
synthesized genomic RNA interacts with newly synthe-
sized nucleocapsid protein and associates with the viral
glycoprotein modified membranes of the Golgi appa-
ratus, thus forming virions. Mature virions migrate to the
host cell membrane where they may exit or wait until
cell death. Whether this process occurs with the agent
of SARS is currently unknown.
Also of interest, coronaviruses readily change their
genetic makeup with a high frequency of mutations and
recombination between new strains. These activities are
even higher than for most RNA viruses and may be the
reason for the appearance of the new SARS coronavirus
(Ksiazek and others 2003). It is likely that SARS is a
recombinant of animal viruses. Several animal corona-
viruses have been known to cause serious disease in-
cluding avian infectious bronchitis virus of chickens and
coronavirus infections of rats (Brooks and others 2001).
Porcine respiratory coronavirus caused widespread
epidemics in pigs in Europe during the 1980s. Antibodies
to coronaviruses of one genus are cross-reactive with
those of other genera.
PUBLIC HEALTH MEASURES
In order to protect the general population from SARS
exposure, a number of recommendations have been
made by WHO, CDC, and health care professionals (CDC
2003b). Currently there is no treatment, other than
supportive, and no vaccine is available (CDC 2003c).
Although the mechanism of SARS transmission is some-
what unclear, it does appear that droplet and contact
transmission predominates (CDC 2003d). As with most
agents of disease, avoidance is still the best protection.
As such, the WHO has issued a travel advisory to avoid
going to endemic areas such as China, Singapore, Hong
Kong, and Vietnam. Although Toronto was included in
the advisory, as of 1 May 2003, it has been removed.
People should avoid anyone who may have SARS or
contact with SARS patients. Persons working with sus-
pected cases of SARS should use appropriate hand
washing and respiratory and contact precautions (CDC
2003d). It may be that once transmission is better
defined, eye protection may also be worthwhile. Coro-
naviruses are very stable in the environment. They can
survive on surfaces for up to 3 hours and can be
transmitted by droplets, hand contamination, fomites,
and small particles (MMWR 2003b). Coronavirus-like
particles have been isolated from diarrhea and stool
specimens (Brooks and others 2001). This has led to
some speculation that SARS may be spread through
sewage or poor toilet hygiene. Again, appropriate hand
washing is important (CDC 2003d).
POSTWORD
During the 1970s there was a general attitude that
we had learned all we need to know about infectious
diseases. After all, we could treat or prevent most bac-
terial diseases and were able to prevent many viral
infections. We could not have been more wrong. Soon
there was Legionnaires' Disease, AIDS, multiple anti-
biotic resistant agents, and a whole new host of viral
diseases. SARS is only the latest of what will be many
infectious diseases on the horizon.
If there is a lesson to learn with SARS and its rapid
spread, it is that physicians, health care workers, public
health officials, and indeed, governments cannot hide
from new infectious agents. They do not go away. It is
possible that if isolation and quarantine methods were
used early, the impact of SARS would have been lessened.
Unfortunately, this was not done and SARS is the latest
worldwide concern of health professionals.
As you are aware, our knowledge of SARS and the
viral causative agent is evolving daily. It is difficult for
the authors to decide when it is time to end the research
and writing process. As such, it is our suggestion that, if
you are interested in the topic, you should access several
websites for the most recent information. Such websites
might be: www.cdc.gov/ncidod/sars/; www.who.int/csr/
sars/en/; and www.medscape.com.
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